{"id":"NCT01418937","sponsor":"GlaxoSmithKline","briefTitle":"Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study","officialTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-29","primaryCompletion":"2015-01-09","completion":"2015-01-09","firstPosted":"2011-08-17","resultsPosted":"2015-08-21","lastUpdate":"2018-07-12"},"enrollment":164,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"CervarixTM (GSK580299)","otherNames":[]}],"arms":[{"label":"HPV Group","type":"EXPERIMENTAL"}],"summary":"This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741) study.","primaryOutcome":{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","timeFrame":"Throughout the study period (from Month 0 up to Month 12)","effectByArm":[{"arm":"Cervarix Group","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"26 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":5,"countries":["Brazil"]},"refs":{"pmids":[],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":164},"commonTop":[]}}